论文部分内容阅读
【目的】观察保心康联合常规药物对慢性心力衰竭(CHF)模型大鼠心功能、腺苷酸代谢的影响,探讨保心康治疗CHF的增效作用。【方法】选用60只SD大鼠随机分为假手术组、模型组、保心康组、常规治疗组、常规治疗+保心康组、常规治疗+曲美他嗪组。采用腹主动脉缩窄术复制慢性心力衰竭大鼠模型。各治疗组分别给予保心康(1 020 mg/kg)、常规治疗(美托洛尔10 mg/kg、卡托普利5 mg/kg、地高辛0.022 5 mg/kg)、曲美他嗪(10 mg/kg)6周,以心脏彩超测定各组大鼠的心功能,并采用高效液相色谱法检测心肌组织腺苷酸(ATP、ADP、AMP)含量。总腺苷酸量(TAN)=ATP+ADP+AMP,能荷(EC)=(ATP+0.5×ADP)/TAN。【结果】心脏彩超显示常规治疗+保心康组大鼠的心脏小于模型组及常规治疗组,左室射血分数、心输出量显著高于模型组及常规治疗组,ATP、TAN、EC水平显著增高,ADP、AMP水平显著降低(均P<0.05或P<0.01)。常规治疗+保心康组与常规治疗+曲美他嗪组比较,心脏大小、左室射血分数、心输出量,以及ATP、ADP、AMP、TAN、EC水平差异均无统计学意义(P>0.05)。【结论】保心康可以改善CHF大鼠心肌的能量代谢障碍,保心康对CHF的常规药物治疗具有一定的增效作用。
【Objective】 To observe the effect of Baoxinkang combined with routine drugs on cardiac function and adenylate metabolism in chronic heart failure (CHF) model rats and to explore the synergic effect of Baoxinkang on CHF. 【Methods】 Sixty SD rats were randomly divided into sham-operated group, model group, Baoxinkang group, conventional treatment group, conventional treatment + Baoxinkang group, conventional treatment + trimetazidine group. Rat model of chronic heart failure was reproduced by abdominal aortic constriction. Each treatment group was given Baoxinkang (1 020 mg / kg), conventional treatment (metoprolol 10 mg / kg, captopril 5 mg / kg, digoxin 0.022 5 mg / kg), trimetazidine (10 mg / kg) for 6 weeks. The cardiac function of rats in each group was measured by echocardiography. The contents of adenosine monophosphate (ATP, ADP, AMP) in myocardium were detected by high performance liquid chromatography. Total TAN = ATP + ADP + AMP, EC = (ATP + 0.5 × ADP) / TAN. 【Results】 Cardiac color Doppler ultrasound showed that the heart of rats in conventional therapy + Baoxinkang group was smaller than that in model group and conventional treatment group. The left ventricular ejection fraction and cardiac output were significantly higher than those in model group and conventional treatment group. The levels of ATP, TAN and EC (P <0.05 or P <0.01). Cardiac size, left ventricular ejection fraction, cardiac output, and ATP, ADP, AMP, TAN and EC levels were not significantly different between conventional treatment + Baoxinkang group and conventional treatment + trimetazidine group (P > 0.05). CONCLUSION: Baoxinkang can improve the energy metabolism disorder of myocardium in CHF rats, and Baoxinkang has a synergistic effect on the conventional drug treatment of CHF.